My latest column for Inside Story magazine evaluates the TGA’s recent move to legalise therapeutic use of psilocybin and MDMA for severe, treatment-resistant depression and PTSD.
It is an interesting case study of delegated authority, and a pleasant change from the usually deranged politics of the ‘drugs debate,’ but who will actually get the benefits?